Hair loss — whether androgenetic alopecia (male/female pattern), alopecia areata (autoimmune), or post-inflammatory hair loss — involves either follicle miniaturization, immune-mediated follicle destruction, or disruption of the hair growth cycle. MSC-derived exosomes and paracrine factors have demonstrated the ability to reactivate dormant follicles and reduce scalp inflammation.
How MSCs Influence Hair Follicles
Hair follicles cycle through growth (anagen), regression (catagen), and rest (telogen) phases. MSCs secrete Wnt pathway activators, FGF-7 (KGF), and VEGF — all of which promote the transition from telogen (rest) to anagen (active growth). In alopecia areata, where the immune system attacks hair follicles, MSC immunomodulation suppresses the attacking CD8+ T-cells.
Delivery Methods
For scalp conditions, MSC-conditioned medium (exosomes and growth factors derived from MSC culture) is delivered via direct scalp injection, sometimes combined with IV infusion for systemic immunomodulation in alopecia areata. Results are typically visible at 3–6 months, with peak improvement at 12 months.
Realistic Outcomes
MSC therapy for hair loss works best when follicles are still present (even dormant) — not when follicles have been completely replaced by fibrotic tissue (as in end-stage cicatricial alopecia). Your physician will assess whether your specific hair loss pattern and timeline make you a suitable candidate.